Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Venture Capitalists Have A Growing Interest In Comparative Effectiveness

Executive Summary

Venture capitalists are taking a growing interest in the impact of comparative effectiveness research on future drug products and how results might affect products' ability to gain coverage by third-party payers

You may also be interested in...



Lack Of Cost-Effectiveness Analysis For Products In Development Could Affect Company Valuations, Attorney Mahinka Says

With payers playing a more prominent role in determining access to drugs, developers will need to focus more on the comparative value of a drug throughout the development cycle, including cost. That value equation also will become an important part of the M&A landscape, attorney Stephen Mahinka says.

CER Could Lead To $10 Bil. Per Year Drop In R&D – Think Tank Analysis

Investments in drug and medical device research and development will decrease as comparative effectiveness research conducted under the Patient-Centered Outcomes Research Institute begins to gain traction, Benjamin Zycher, senior fellow at Pacific Research Institute, predicts.

CER Could Lead To $10 Bil. Per Year Drop In R&D – Think Tank Analysis

Investments in drug and medical device research and development will decrease as comparative effectiveness research conducted under the Patient-Centered Outcomes Research Institute begins to gain traction, Benjamin Zycher, senior fellow at Pacific Research Institute, predicts.

Related Content

Topics

UsernamePublicRestriction

Register

PS052350

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel